#4737
Anonymous

    I think it will certainly decrease volumes in the clinic. I also think that it could impact which treatment providers choose – pembrolizumab vs. nivolumab. I know that certain providers chose pembro based on the fact that dosing is less frequent while others who like to see patients more frequently chose nivo. I do know that my nivo patients will be thrilled with the once monthly dosing!

    Latest Activity